



## Advances in Immunotherapy for Hematological Malignancies

Guest Editors:

**Dr. Anilkumar  
Gopalakrishnapillai**

**Dr. Jonathan Fisher**

**Dr. Raju K. Pillai**

Deadline for manuscript  
submissions:  
**closed (31 August 2023)**

### Message from the Guest Editors

Wish you all a very happy and productive new year 2022!

In this issue, we are inviting original articles/focused reviews reporting such advancements that change the landscape of treatment for hematological malignancies. These articles are not limited to approaches such as chimeric antigen receptor (CAR) T-cells (CAR-T), CAR macrophages (CAR-Ma), CAR natural killer cells (CAR-NK), UltraCAR-T, and bispecific T cell engagers (BiTES) but also include drug immunoconjugate, cancer vaccine, and various combination strategies to improve the efficacy or avoid immunotherapy-based treatment resistance.

### Keywords

- immunotherapy
- hematological malignancies
- CAR-T
- BiTES
- CAR-NK
- CAR-Ma
- UltraCART
- DNA vaccine
- immunoconjugate
- combination therapies
- immune checkpoint blockade





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI